Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.

Blood advances - 12 Dec 2023

Landsburg Daniel J, Morrissette Jennifer Jd, Nasta Sunita D, Barta Stefan K, Schuster Stephen J, Svoboda Jakub, Chong Elise A, Bagg Adam

Abstract excerpt

Genetic subgroups of diffuse large B-cell lymphoma (DLBCL) have been identified through comprehensive genomic analysis; however, it is unclear whether this can be applied in clinical practice. We assessed whether mutations detected by clinical laboratory mutation analysis (CLMA) were predictive of outcomes in patients with newly diagnosed DLBCL/high-grade B-cell lymphoma (HGBL). Patients diagnosed from 2018 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophosphamide
Share to Doxorubicin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lymphoma, Large B-Cell, Diffuse

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Rituximab

Share to Tumor Suppressor Protein p53

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 37851898
DOI: 10.1182/bloodadvances.2023011384
PMCID: PMC10698538

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.PMID 37851898Read ↗

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

TP53 mutation predict poor prognosis in diffuse large B-cell lymphoma: a single-center study.Semantic proximity Read ↗

Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.Semantic proximity Read ↗

Prognostic Impact of TP53 Mutations in Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

TP53 mutations predict poor prognosis in diffuse large B-cell lymphoma: A single-center studySemantic proximity Read ↗

Prognostic Analysis of Diffuse Large B-Cell Lymphoma Patients Based on Clinical Characteristics, TP53 Mutation Status, and Number of Co-mutated GenesSemantic proximity Read ↗

Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas.Semantic proximity Read ↗

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.Semantic proximity Read ↗

Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine.Semantic proximity Read ↗

TP53 and OSBPL10 alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosisSemantic proximity Read ↗

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.